
BioSpectrum the business of Bio & Health Sciences ASIA EDITION

MENA region gets first Center for Advanced Neuro Biochemical Diagnostics

April 23, 2025 | News

Center aims to establish the world's most advanced clinical diagnostic laboratory for brain disorders



The National Reference Laboratory (NRL), part of the M42 Group, is establishing the MENA (Middle East and North Africa) region's first Center for Advanced Neuro Biochemical Diagnostics dedicated to early detection, in partnership with Neurocode International, global leader of neurology diagnostic solutions, setting a new regional benchmark in the fight against Alzheimer's disease.

Announced on the sidelines of Abu Dhabi Global Health Week, the Center for Advanced Neuro Biochemical Diagnostics, based in Abu Dhabi, is a pioneering step toward reducing Alzheimer's cases in the UAE and wider region and transforming neurological diagnostics worldwide.

The Center for Advanced Neuro Biochemical Diagnostics aims to revolutionise Alzheimer's diagnosis by offering screening as early as age 40 through cutting-edge blood-based tests, ensuring timely intervention and significantly improving patient outcomes.

Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, said: "Launching the region's first Center for Advanced Neuro Biochemical Diagnostics marks a significant milestone in our commitment to advancing healthcare. This center will revolutionise the early, proactive detection of Alzheimer's, underscoring our dedication to and the importance of preventive health. By focusing on early intervention, we aim to reduce the impact of Alzheimer's and improve the quality of life for patients in the UAE and beyond."

The center aims to establish the world's most advanced clinical diagnostic laboratory for brain disorders, guiding global clinicians in precision detection and ushering in a new era of neurological diagnostics. Its research will be published in top scientific journals, sharing findings with the wider medical community. The laboratory will also offer world-class technology and clinical infrastructure, ensuring standardized test levels and cut-offs across leading laboratories for consistent, high-quality care.

The launch marks not only a first for the MENA region but also a new era in global Alzheimer's research.